WO2025148866 - USE OF DIHYDROBERBERINE OR ITS DERIVATIVES FOR REGULATING GLP-1
National phase entry is expected:
Publication Number
WO/2025/148866
Publication Date
17.07.2025
International Application No.
PCT/CN2025/070992
International Filing Date
07.01.2025
Title **
[English]
USE OF DIHYDROBERBERINE OR ITS DERIVATIVES FOR REGULATING GLP-1
[French]
UTILISATION DE LA DIHYDROBERBÉRINE OU DE SES DÉRIVÉS POUR LA RÉGULATION DU GLP-1
Applicants **
NANJING NUTRABUILDING BIO-TECH CO., LTD.
Inventors
YI, Ronghua
WELLS, Shawn
ZHANG, Qianjing
LIAO, Kylin
Priority Data
PCT/CN2024/071090
08.01.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1922 | |
| EPO | Filing, Examination, Granting | 15215 | |
| Japan | Filing, Examination, Granting | 2387 | |
| South Korea | Filing, Examination, Granting | 2573 | |
| USA | Filing, Examination, Granting | 5140 |
Total:
27,237
Contact Us
Abstract[English]
Provided herein are novel compositions and methods for improving or regulating GLP-1 levels, or stimulating GLP-1 secretion in a subject. The composition may comprise dihydroberberine (DHB), or a physiologically acceptable salt, polymer, ester, acid, or an analog or derivative thereof.[French]
L'invention concerne de nouvelles compositions et méthodes permettant d'améliorer ou de réguler des taux de GLP-1, ou de stimuler la sécrétion du GLP-1 chez un patient. La composition peut comprendre de la dihydroberbérine (DHB) ou un sel, polymère, ester, acide physiologiquement acceptable de celle-ci, ou un analogue ou dérivé de celle-ci.